Ascendis Pharma A/S (NASDAQ:ASND) Research Coverage Started at Royal Bank of Canada
Royal Bank of Canada initiated coverage on shares of Ascendis Pharma A/S (NASDAQ:ASND – Free Report) in a research note issued to investors on Wednesday, MarketBeat.com reports. The firm issued an outperform rating and a $205.00 price target on the biotechnology company’s stock. Several other research analysts have also recently commented on ASND. Cantor Fitzgerald […]
Royal Bank of Canada initiated coverage on shares of Ascendis Pharma A/S (NASDAQ:ASND – Free Report) in a research note issued to investors on Wednesday, MarketBeat.com reports. The firm issued an outperform rating and a $205.00 price target on the biotechnology company’s stock. Several other research analysts have also recently commented on ASND. Cantor Fitzgerald […]